BioSpace News Archive

Leading health insurer and health care services company Humana Inc. announced that it has named David Dintenfass as President of Enterprise Growth.

LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, is proud to issue an RFA (Request for Application) for the Career Development Award program.

Tourmaline Bio, Inc. today announced the pricing of an underwritten public offering of 4,615,384 shares of its common stock, at a public offering price of $32.50 per share.

Evolent Health, Inc. today announced it will release its fourth quarter 2023 financial results on Thursday, Feb. 22, 2024, after market close, with a conference call to follow at 5 p.m. ET.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data at CMR 2024 demonstrating favorable effects on cardiac structure, function and fibrosis related to treatment with aficamten in FOREST-HCM.

Accuray Incorporated announced that the Providence Swedish Radiosurgery Center in Seattle, Washington is enhancing its cancer treatment capabilities with the purchase of the latest generation CyberKnife® S7™ System, the hospital’s second CyberKnife radiation delivery device purchase.

Wiley (NYSE: WLY and WLYB), one of the world’s largest publishers and a global leader in research and learning, will host its Investor Update today at 10 am E.T. to discuss the company’s business and financial outlook.

Prime Medicine, Inc. (Nasdaq: PRME) today announced that the Cystic Fibrosis Foundation (CF Foundation) has agreed to provide the Company with up to $15 million to support the development of Prime Editors for the treatment of Cystic Fibrosis (CF).

Ocular Therapeutix, Inc. (NASDAQ:OCUL) today announced that the U.S. Food and Drug Administration (FDA) has agreed to a Special Protocol Assessment (SPA) Agreement Modification for the Company’s pivotal Phase 3 SOL clinical trial of AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD).

Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, announced a streamlined leadership structure designed to focus on pipeline advancement and align with Kronos Bio’s current operating needs.